Joseph Thome
Stock Analyst at TD Cowen
(0.23)
# 4,182
Out of 4,868 analysts
18
Total ratings
20%
Success rate
-27.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $28.19 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $15.00 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $291.72 | +37.12% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $11.02 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $29.33 | +15.92% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $1.80 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.48 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $50.43 | -40.51% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $4.63 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $31.90 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.24 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.48 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $102.90 | +26.34% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.60 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.03 | - | 1 | Nov 23, 2021 |
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $28.19
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $15.00
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $291.72
Upside: +37.12%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $11.02
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $29.33
Upside: +15.92%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $1.80
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $50.43
Upside: -40.51%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.63
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $31.90
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.24
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.48
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $102.90
Upside: +26.34%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.60
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.03
Upside: -